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Abstract Functionally active complement system and
complement regulatory proteins are present in the normal
human and rodent eye. Complement activation and its
regulation by ocular complement regulatory proteins con-
tribute to the pathology of various ocular diseases including
keratitis, uveitis and age-related macular degeneration.
Furthermore, a strong relationship between age-related
macular degeneration and polymorphism in the genes of
certain complement components/complement regulatory
proteins is now well established. Recombinant forms of
the naturally occurring complement regulatory proteins
have been exploited in the animal models for treatment of
these ocular diseases. It is hoped that in the future
recombinant complement regulatory proteins will be used
as novel therapeutic agents in the clinic for the treatment of





Complement has long been recognized as a critical
component of the innate immune system [1–6]. It com-
prises of soluble and surface proteins that play a central role
in host defense against infection and in the modulation of
antigen-specific immune and inflammatory responses [4,
5]. Thus, complement also serves as a bridge between
innate and adaptive immunity. The complement system can
be activated by three proteolytic cascades namely, the
classical, the alternative, and the lectin pathways (Fig. 1).
Although the initial signal for the activation of each cascade
differs, complement activation via these pathways triggers a
sequence of biologic reactions in which each component is
activated by the upstream component [3, 5]. This sequential
activation of complement components by all three path-
ways leads to the formation of membrane attack complex
(MAC). Under normal conditions, the activation of the
complement system is kept under tight control by the
coordinated action of soluble and membrane-associated
complement regulatory proteins (CRegs). However, inter-
ference with the function and/or expression of CRegs leads
to unwanted host tissue damage and tissue pathology due to
unregulated complement activation [7, 8].
CRegs can be broadly categorized into two classes—
membrane-bound CRegs and soluble CRegs (Fig. 1).
Membrane-bound CRegs (Fig. 1) include decay-accelerat-
ing factor (DAF, CD55), membrane co-factor protein
(MCP, CD46), complement receptor 1 (CR1, CD35), and
membrane inhibitor of reactive lysis (MIRL, CD59). DAF,
a glycosylphosphatidylinositol (GPI)-anchored protein pre-
vents the activation of the complement system by inhibiting
the formation of C3 and C5 convertases of both the
classical and alternative pathways and accelerating the
decay of these convertases [9, 10]. However, DAF does not
irreversibly inactivate C3b and C4b and, after interaction
with DAF, these molecules still possess cytolytic activity.
MCP a transmembrane glycoprotein regulates the comple-
ment cascade by serving as a co-factor for serine protease
factor I, which irreversibly inactivates the hemolytic
potential of C3b and C4b [11, 12]. CR1 has been reported
to possess both decay-accelerating and co-factor activities
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by GPI anchors. CD59 acts at the terminal step of
complement activation and prevents the formation of
membrane attack complex (MAC, C5b-9 complex), the
final activation product of all three complement cascades
by blocking the incorporation of C9 [14, 15]. Crry (5I2
antigen) is a C3 convertase inhibitor that possesses both
decay-accelerating and membrane co-factor activities and
present only in rodents [16, 17]. However, DAF, MCP, and
CD59 have also been identified and characterized in
rodents [18–23].
C1 inhibitor (C1INH), C4 binding protein (C4bp),
complement factor H (CFH), complement factor I (CFI),
S-protein and clustrin, are the examples of important
soluble CRegs (Fig. 1). C1INH regulates activation of the
classical complement pathway by inactivating the protease
function of activated C1 complex. It also prevents sponta-
neous activation of C1 and binding to the zymogen forms
of C1r and C1s [24]. C4bp acts as a co-factor for CFI,
catalyzing the cleavage and inactivation of C4b [25]. CFH
inhibits C3 activation by binding to C3b and acting as a co-
factor for factor I-mediated cleavage of C3b and also has
decay-accelerating activity for the alternative pathway C3
convertase, C3bBb. It also competes with factor B for
surface-bound C3b [26]. Both clustrin and S-protein
prevent the formation of MAC [6]. Soluble forms of
MCP, DAF, CR1, CD59, and Crry have been reported to
be present in various biological fluids in both humans and
rodents [27–30]. Thus, a wide variety of CRegs (both
membrane bound and soluble) have evolved to create
efficient checkpoints at critical steps of complement
cascades so that the host could be protected from the
inadvertent activation of complement on its own tissue
(Fig. 1).
Since complement is a powerful cytotoxic defense
system, regulation of complement activation is crucial
for host tissue damage control during inflammation
especially in a sensitive organ like the eye. The eye is
an immunologically privileged site and ocular immune
privilege does not refer to the absence of immune
system but, rather its fine regulation [31]. The studies
discussed in this article highlight the role of complement
activation and regulation in the protection of the normal
eye. In addition, the studies discussed below demonstrate
the importance of interplay between complement activa-
tion and complement regulation in the development of
vision-threatening complications such as keratitis, uveitis,
and macular degeneration.
Fig. 1 Complement system and complement regulatory proteins
(CRegs). The complement system can be activated through three
pathways and complement activation triggers a sequence of biological
reactions which result in the generation of effector molecules (e.g.,
C3a, C3b, C5a, MAC) with potent immunological activities. The
classical pathway can be activated by antigen-antibody complexes or
by substances such a C-reactive protein. C1, C2, C4, and C3 are the
components of the classical pathway. Activation of the alternative
pathway does not require the presence of an antibody; C3, factor B,
factor D, and properdin are the components of the alternative pathway.
Like the alternative pathway, the activation of the lectin pathway is
also antibody independent and can be achieved by interaction of serum
lectins (e.g., mannose-binding protein, MBL), with sugar residues
present on the bacterial cell wall. All three pathways converge on a
common reaction that results in the formation of an enzyme—C3
convertase. This enzyme cleaves C3 into C3a and C3b. C3b forms C5
convertase that ultimately leads to the formation of membrane attack
complex (MAC). The complement cascade is regulated at different
check points (shown with black blocks) by CRegs. The soluble CRegs
are shown in white boxes and the membrane-bound CRegs are shown
in gray boxes
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It is important that we discuss the role of complement and
CRegs in ocular protection under normal conditions before
discussing their importance in ocular pathology. As
mentioned above, the eye is an immune-privileged organ
[31] and is highly vulnerable to various immunological
insults. Therefore, it is not surprising that the complement
system, which represents the first line of defense, plays an
important part not only in protecting the eye from
immunological insults but also in maintaining the im-
mune-privileged state of the eye. Our results and several
other independent studies have demonstrated the presence
of various components of the complement system in the
normal eye [2, 32–37]. We have further shown that ocular
complement components are not just silent bystanders but
are chronically active at a low level in normal eye [32]. We
reported that both iC3b (activation product of C3) and
MAC (end product of complement activation) are present in
normal rat eye indicating that the complement system is
continuously activated at a low level in the normal eye [32].
In 2003, we documented that the interaction between
complement activation product iC3b and its receptor is
vital for the creation of immunosuppressive environment
that leads to the induction and the maintenance of ocular
immune privilege and protection of intraocular structures
that are critical for vision [38]. The presence and expression
pattern of CRegs in the normal human eye was first described
by us [33]. We reported that membrane-bound CRegs—
MCP, DAF, and CD59—are differentially expressed in
normal human and eyes [33]. Our studies along with other
independent studies that were performed later demonstrated
that Crry and CD59 (membrane bound and soluble) are also
present in the normal rodent eye [32, 34, 35]. We have
further shown that ocular CRegs are functionally active and
tightly regulate the activation of intraocular complement [27,
32]. Functional inhibition of ocular CRegs using specific
antibodies resulted in unregulated complement activation
leading to severe intraocular inflammation in normal animals
[32]. Furthermore, complement inhibitory activity in normal
human intraocular fluid was blocked by inhibiting the
function of MCP, DAF, and CD59 [27].
Thus, our results clearly established that within the
normal eye the complement system seems to perform two
important functions. First, the chronic low level of
complement activation serves as a primary defense mech-
anism of the eye against pathogenic infection and is finely
regulated by the soluble and membrane-bound intraocular
complement regulatory proteins. This enables destruction of
the putative pathogen without inadvertent damage of ocular
tissue, which is vital for the maintenance of vision. Second,
complement activation products (such as iC3b) generated as
a result of the low level of complement activation results in
the selective suppression of harmful Tcell responses. In this
role complement protects the eye from innocent bystander
destruction associated with the T cell response to the
invading pathogens. Complement components and CRegs
present in normal tears have also been reported to be
functionally active and have been proposed to serve as first
line of defense in protecting the eye [36]. However,
additional studies are required to determine the role of the
complement system in normal tears.
Role of complement in corneal disease
The cornea is constantly exposed to various physical as
well as immunological insults. Indeed the normal cornea is
well equipped to protect itself from these insults and has
been shown to possess functional complement activity [39–
46]. In addition, low levels of C3, C3 split products, and
MAC were detected in the normal cornea [32, 39, 46]. This
observation further proves that low level of complement
activation is taking place in the normal cornea since
complement activation is necessary for the generation of
these products. Studies reported in the literature suggest
that complement cascade can be aggressively activated in
the cornea during an immune and inflammatory reaction
[45, 46]. Two reports by Mondino and colleagues described
interesting sets of experiments [45, 46]. In these experi-
ments, the normal cornea from human donors was exposed
to lipopolysaccharide (LPS), ribitol teichoic acid immune
complex, acid (HCl), or alkali (NaOH) separately and the
generation of anaphylatoxins—C3a, C4a, and C5a—as well
as MAC in the corneas was monitored. It was reported that
anaphylatoxins—C3a, C4a, and C5a—could be generated
when the cornea was injured with LPS, immune complexes,
acid, or alkali. Interestingly MAC could only be generated
when the cornea was exposed to LPS or immune
complexes. Cornea failed to generate MAC when insulted
with acid or alkali. The immune response mounted to LPS
or immune complex is similar to that generated against
infectious agents like gram-negative bacteria. Indeed the
complement system has been shown to play a critical role
in protection against Pseudomonas aeruginosa infection
that causes keratitis [47, 48]. Additionally, complement
activation is believed to play an important role in ulceration
of human cornea induced by gram-negative bacteria [49].
The aforementioned observations have important clinical
implications. If in future anti-complement agents were to be
considered for the treatment of corneal pathology, anaphy-
latoxins would be an ideal target for the patient presenting
with chemical injury such as exposure to acid or alkali. On
the other hand, in the case of bacterial infection both anti-
anaphylatoxin and anti-MAC therapy should be considered.
Although as discussed below the cornea possesses the
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complement-mediated damage, it may not be able to
upregulate various CRegs to an appropriate level during
an acute episode of complement activation as observed
during chemical insults or acute bacterial infection. In such
cases, topical application of recombinant CRegs could be
beneficial and serve as a better alternative for intervention.
Enhanced complement activation can cause damage to
the autologous corneal tissue during an infection or
inflammation. Membrane-bound CRegs such as MCP,
DAF, Crry (Fig. 2a), and CD59 (Fig. 2b) are expressed in
the different layers of the cornea to protect this tissue from
complement-mediated damage [27, 33, 50]. Interestingly,
compared to corneal stroma and corneal endothelium,
various CRegs are very strongly expressed on the corneal
epithelium [33] (Fig. 2a and b). This high expression of
CRegs on the corneal epithelium is crucial for the
protection of the cornea because the cornea is continually
exposed to various pathogens including bacteria. These
bacteria produce phospholipase and other enzymes which
can remove GPI-anchored DAF and CD59 from the corneal
surface [51]. Thus, in the absence of a very high expression
of CRegs on the corneal epithelium, bacterially induced
loss of DAF and CD59 could be deleterious to the cornea
and lead to vision loss after the putative pathogen has been
destroyed by the complement system. To investigate if a
deficiency or abnormality in the expression of CRegs may
play a role in ocular surface disease, systemic examination
of corneal tissue from patients with different diseases such
as pseudophakic bullous keratopathy, HSV-1 keratitis, and
herpes zoster scleritis is needed.
Role of complement in autoimmune uveitis
Uveitis, the inflammation of the uveal tract, can be
classified anatomically as anterior, intermediate, posterior,
or diffuse (panuveitis) depending on the segment of the eye
that is affected. Each year, approximately 17% of active
uveitis patients experience some degree of vision loss [52].
Uveitis may be idiopathic, associated with systemic
diseases such as Behçet’s disease, and Vogt–Koyanagi–
Harada disease or resulting from a variety of infectious
agents. Inflammation resulting from uveitis may lead to
conditions like cataract, glaucoma, and cystoid macular
edema that may cause irreversible vision loss. Anterior
uveitis is the most common form of uveitis, and the most
common form of anterior uveitis is of unknown (i.e.,
idiopathic) etiology [52].
Although the exact cause of the disease is still unknown,
a wide array of studies using different animal models have
established that the inflammation in uveitis is due to an
autoimmune response to various ocular antigens [53–56].
Unfortunately, almost all of the studies in the past three
decades have focused on the role of T cells in the
pathogenesis of uveitis [54, 57, 58]. Very few laboratories
have investigated the role of the complement system in the
development of autoimmune uveitis [32, 58–66].
Through our recent studies, the critical role of comple-
ment and complement regulatory proteins (CRegs) in the
pathogenesis of idiopathic anterior uveitis was addressed
and recognized. Our laboratory has used experimental
autoimmune anterior uveitis (EAAU)—an animal model
of human autoimmune anterior uveitis—to investigate the
role of the complement system, a significant and previously
neglected facet of uveitis [53, 62, 63]. EAAU is induced by
injecting bovine melanin-associated antigen emulsified in
Freund’s complete adjuvant, in the foot pad of Lewis rats
[53]. The onset of the disease (days 12–14 post immuni-
zation) is marked by inflammation of the iris/ciliary body
followed by massive infiltration of the inflammatory cells
in the anterior segment of the eye during the peak (days 16–
19 post immunization) of EAAU (Fig. 3). The inflamma-
tion resolves after approximately 3 weeks, and the eye
returns to the normal state with no apparent sign of any
tissue damage (Fig. 3). Interestingly, studies from our
laboratory have demonstrated that the activation of the
complement system is critical for the development of
EAAU [62]. During EAAU, the complement system is
activated (detected by Western blot analysis for iC3b) in the
eye, and the kinetics of complement activation follows a
pattern that is similar to the clinical course of the disease.
Furthermore, depletion of the complement system of the
host resulted in complete inhibition of EAAU. In comple-
ment-depleted rats, the levels of IFN-γ, IP-10, ICAM-1,
and LECAM-1 were extremely low compared to the
complement-sufficient rats during EAAU. Our observations
suggest that the activation of the local complement system
plays a critical role in the development of inflammation
during EAAU and suppression of intraocular complement
system, thus may provide a successful strategy for uveitis
therapy. At present, the exact mechanism and pathways
Fig. 2 Complement regulatory proteins in normal cornea. The figure
shows immunofluorescent staining for Crry (a) and CD59 (b) in the
cornea of naive Lewis rat. Objective magnification ×20. Epi
Epithelium, S stroma, Endo endothelium, AC anterior chamber
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not known. It is also not known if the increase in
complement components in the anterior segment of the
eye is due to the upregulation of their synthesis by resident
ocular cells or is a result of spillover from the systemic
complement system. Previous studies from our laboratory
established that a functionally active complement system is
present in the anterior segment of the eye because when a
well-known activator of complement such as zymosan was
injected in the anterior chamber, severe anterior uveitis was
induced. This zymosan-induced uveitis was due to the
activation of the complement system because anterior
uveitis was completely inhibited when the complement
system of the host was depleted [32]. Furthermore, we and
others have reported the presence of various complement
components in aqueous humor as well as other parts of the
normal eye [32, 39, 41, 59, 61]. These observations taken
together suggest that ocular complement is activated during
the course of EAAU and the inhibition of the intraocular
complement system may lead to more effective manage-
ment and/or treatment of autoimmune uveitis.
When considering anti-complement therapy, we cannot
ignore the role of CRegs in the resolution of autoimmune
uveitis. We have demonstrated that the functionally active
CRegs downregulate intraocular complement activation and
are critical to protect the ocular tissues from complement-
mediated damage during EAAU [63]. We observed that
various CRegs were upregulated during the course of
EAAU on the resident ocular tissue and this upregulation
was not due to the infiltrating inflammatory cells because
the levels of CRegs remained upregulated after the
resolution of the disease when all the infiltrating cells were
cleared from the anterior segment of the eye [63].
Furthermore, when the function or expression of CRegs
was inhibited in vivo, more severe EAAU with early onset
and delayed resolution was observed. These observations
demonstrate that ocular tissue can protect itself by
upregulating various CRegs during uveitis and provide
strong evidence for the use of recombinant CRegs as
therapeutic agents in the treatment of autoimmune uveitis.
Activation of the complement system has also been
reported in other animal models of anterior uveitis such as
endotoxin-induced uveitis (EIU) [64, 65]. In EIU, it was
demonstrated that the complement system is critical for the
development of inflammation, and there is a local activation
of the complement system as evident by accumulation of
complement components (C1q, C3, and C4) in various
parts of the eye during inflammation [66]. Activation of the
complement system was also implicated in experimental
allergic uveitis [67]. Using experimental autoimmune
uveoretinitis (EAU) animal model, the complement system
has been reported to play an important role in the
pathogenesis posterior uveitis [68]. Recently, Read and co-
workers demonstrated that the transgenic mice that express
soluble Crry in the retina had decreased incidence and
severity of EAU [68]. In these transgenic mice, EAU was
not completely suppressed. This may be due to relatively
low levels of Crry expressed compared with the levels that
Fig. 3 Clinical and histologic pictures of rat eye during different
stages of experimental autoimmune anterior uveitis (EAAU). No
inflammation could be detected in the iris (I) and the ciliary body (CB)
after clinical (a) and histologic (d) examination at day 8 post
immunization (before the onset of EAAU). At the peak of disease
(day 19 post immunization) the anterior chamber (AC) appeared
cloudy and opaque due to the presence of proteinaceous material and
inflammatory cells (b). Histopathologic picture of rat eye at the peak
of EAAU (e) revealed severe inflammation of the iris (I) and ciliary
body (CB). Heavy infiltration in the anterior chamber (AC) with
spillover into the anterior vitreous was also observed at this time point.
The eye appeared normal both clinically (c) and histologically (f) after
the resolution of EAAU (day 30 post immunization). Objective
magnification ×10
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system. It is possible that a higher dose of exogenous Crry
or similar CReg may result in complete inhibition of EAU.
Thus, these studies provide strong evidence that the
complement system and CRegs play an important role in
the pathogenesis of autoimmune uveitis and provide
alternative approaches for the development of effective
therapy. More research in the future will present us enough
information to develop anti-complement therapy for uveitis.
Hopefully, in the future, complement inhibitors might be
used as novel anti-uveitic agents in the clinic for the
treatment of this important form of human ocular disease.
Role of complement in age-related macular
degeneration
Age-related macular degeneration (AMD) is the most
common cause of legal blindness worldwide among the
elderly over the age of 50. Approximately 1.8 million
people in the United States alone have AMD and it is
projected that by 2020, roughly 2.9 million people will
develop this disease [69–71]. In AMD, there is a progres-
sive destruction of the macula leading to the loss of central
vision. AMD is classified into non-exudative (dry type) and
exudative (wet type) [69–71]. In the dry type of AMD,
drusen—small yellow deposits—are formed between the
retinal-pigmented epithelium (RPE) and Bruch’s membrane
[72]. In wet-type AMD, abnormal vessel growth takes place
from choroid, termed choroidal neovascularization (CNV),
under the retinal pigment epithelium [71, 72]. Although
several risk factors are associated with AMD, the exact
pathogenesis still remains unknown. The last few years
have witnessed an amazing series of research establishing
the central role of the complement system in the pathogen-
esis of AMD both in humans and in experimental animals.
Various studies in the literature have indicated a potential
role for complement in drusen formation in the non-
exudative form of AMD in humans [73–75]. Complement
components, complement activation products (C3a, C5a,
MAC), and complement regulatory proteins (CD46,
Vitronectin) have been localized in drusen in patients with
AMD [73–75].
The discovery of allelic variants of complement factor H
(CFH) as a major risk factor for AMD has become a
landmark study [76–79]. The polymorphism that gives rise
to this allelic variant of CFH results from a tyrosine to
histidine replacement at position 402. The “high risk”
variant, i.e., homozygous for histidine residue at position
402 is associated with five- to sevenfold increased risk of
AMD [76–79]. CFH consists of 20 short consensus repeats
(SCRs) and the polymorphic site 402 resides in SCR7.
SCR7 contains the binding site for C3b, glycosaminogly-
cans (GAG) and C-reactive protein (CRP). The polymor-
phism at position 402 in SCR7 reduces the binding affinity
to CRP [80] and GAG [81]. Binding of CFH to CRP and
GAG plays an important role in the regulation of the
alternative pathway. Thus the polymorphic form of CFH
with histidine at position 402 may have reduced ability to
regulate the activation of the alternative pathway. This may
lead to uncontrolled activation of alternative pathway which
may result in the development of AMD. The loss of
regulatory activity of CFH due to polymorphism can have a
direct effect on the predisposition of the eye to AMD as it
has been shown recently that CFH is expressed locally in
the optic nerve, retina, and retinal pigment epithelium [82].
The importance of CFH in AMD was further demonstrated
in a recent study. It was reported that the aged mice
genetically deficient in CFH (cfh−/−) develop spontaneous
changes in retina (e.g., photoreceptor dysfunction, in-
creased deposition of C3 in retina, thinning of Bruch’s
membrane) which is consistent with those seen in AMD
[83].
Polymorphic variants of other complement components
havealso beenshowntobeassociatedwithAMD. Inarecent
study, Gold et al. reported that complement components—
factor B (CFB) and complement component 2 (C2)—are
also associated with AMD [84]. In this report, the inves-
tigators identified high risk allele and two protective alleles
for CFB and C2 that were associated with AMD. An
independent study further established a similar association
between CFB, C2, and AMD [85]. More recently, inves-
tigators compared 847 patients with AMD with 701
unaffected people and observed that a variant in the
complement C3 gene affected the risk of developing
AMD [86].
The aforementioned studies establish that the polymor-
phism in the genes of certain complement components and
regulators genetically predisposes some individuals to
AMD. However, we should also pay attention to the fact
that other risk factors for AMD such as alcohol consump-
tion and smoking nicotine can directly affect the level of
complement activation and CRegs. For instance, chronic
ethanol consumption upregulates CFB but downregulates
CFH in mice [87]. Thus, association of alcohol consump-
tion with AMD may be due to its direct effect on the
complement system. Indeed we have reported that chronic
alcohol consumption increases the size of CNV complex in
rat model of laser-induced CNV [88]. Similarly, cigarette
smoking has been shown to decrease the affinity of CFH
for C3 and activate the complement system [89].
In our laboratory, we use a mouse model of laser-
induced CNV to study the role of complement in the
pathogenesis of wet-type AMD. A reliable way to produce
CNV in animals is to rupture Bruch’s membrane with laser
photocoagulation [90–92]. We and others have found that
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photocoagulation is useful to gain insights into the
pathogenesis of new vessel growth from the choroid [90–
96]. In 2005, we demonstrated for the first time using this
animal model that complement activation and generation of
MAC is critical for the development of laser-induced CNV.
In this study, C3−/− mice and anti-C6-treated mice failed to
develop CNV [93]. As mentioned above, the importance of
C3 in the pathogenesis of AMD was recently confirmed by
Yates et al., who established an association of C3
polymorphism with AMD [86]. We further observed that
in the absence of MAC deposition, release of angiogenic
factors such as vascular endothelial growth factor (VEGF),
TGF-β2, and β-FGF was inhibited. This is a crucial
observation as it suggests that the complement system is a
potential therapeutic target for the treatment of CNV.
Subsequently, we reported that the activation of comple-
ment by alternative pathway is responsible for MAC
formation in laser-induced CNV. This alternative pathway
activation was due to the decrease in CFH levels and
increase in CFB levels in the RPE/choroid after laser
treatment [94]. In a separate study, we used recombinant-
soluble CD59-Fc chimeric protein to inhibit the formation
of MAC after laser photocoagulation [95]. Treatment of
mice with recombinant-soluble CD59-Fc inhibited the
development of choroidal angiogenesis in the laser-induced
mouse model by blocking MAC formation which in turn
blocked the induction/release of angiogenic growth factors
such as VEGF, β-FGF, and TGF-β2 (Fig. 4). Thus, our
studies suggest that the recombinant forms of CD59 could
be used as a potential drug in the future to treat CNV.
Another potential target could be anaphylatoxins—C3a and
C5a. It was reported that C3a and C5a are present not only
in human drusen but are also localized in the choroid of
mice with laser-induced CNV [97].
Using the mouse model of laser-induced CNV, we
observed that the CH50 levels in the serum of lasered mice
varied when compared to non-lasered mice [93, 94].
Another study demonstrated that the plasma complement
C3a des Arg levels increased in AMD patients compared to
controls [98]. This increase in plasma C3a des Arg
concentration reflects systemic complement activation.
Thus systemic activation of the complement system may
also contribute to the pathogenesis of AMD.
Currently, several different approaches are being used to
treat wet AMD in humans [99]. Unfortunately, these
treatment options have limitations due to their short-term
and serious side effects. Although, photodynamic therapy
(PDT) reduces the rate of vision loss in most patients, it
does not lead to significant improvement in vision.
Furthermore, repeated PDT can cause severe damage to
the posterior segment of the eye and is not cost effective.
Two drugs Lucentis and Macugen are approved by Federal
Drug Administration for the treatment of AMD and both
drugs inhibit vascular endothelial growth factor. One of the
major drawbacks of Lucentis or Macugen is that repeated
Fig. 4 Role of CD59 in laser-induced choroidal neovascularization
(CNV). Laser photocoagulation results in complement activation and
MAC formation in the posterior segment of the eye. MAC is a
complex assembly of C5b to C9 components with multimers of C9
forming a pore in the cell membrane. This causes increased release of
growth factors—VEGF, TGFβ2, and β-FGF—which in turn leads to
the development of CNV. The membrane-bound as well as recombi-
nant-soluble (rs) CD59, bind to C9 and C8 and inhibit the
polymerization of C9 which is prerequisite for MAC formation. In
the absence of MAC, release of angiogenic factors is downregulated.
This inhibits the growth of new vessel from the choroid (CNV)
Semin Immunopathol (2008) 30:85–95 91injections of these drugs are needed to treat AMD.
Repeated injections can cause some serious side effects
including hemorrhage of the eye membrane, eye pain, and
vitreous floaters. Therefore, alternative therapeutic strate-
gies with minimum side effects are required to better treat
AMD patients. We believe that the results derived from the
studies reviewed above would open up the window of
opportunities for the development of anti-complement
therapy in the treatment of AMD.
In view of important developments relative to the role of
the complement system in AMD during the past several
years, we believe that the next decade would be critical for
such studies. We hope that the interest will continue to
grow in the future so that an alternative therapy could be
developed by inhibiting complement activation. Since
untreated CNV leads to the irreversible loss of central
vision, it is important for the pharmaceutical companies to
utilize the knowledge available to them from different
research laboratories and should make every effort to
transfer this knowledge to develop new drugs and therapies
for AMD patients.
Conclusions and clinical implications
During the last decade, a lot of progress has been made to
understand the pathophysiology of corneal diseases, uveitis,
and macular degeneration. Specifically, the studies defining
the role of the complement system in ocular diseases have
drawn a lot of attention. It is an exciting area for future
investigations and the basic questions such as what triggers
the complement activation and which specific pathway is
involved in corneal diseases, uveitis and macular degener-
ation need to be addressed. This understanding will help us
to develop better therapies for ocular diseases in the future
so that blindness could be prevented.
The evidence derived from the studies reviewed here
supports the concept that recombinant complement regula-
tory proteins may be therapeutically useful in the preven-
tion of ocular tissue damage and in the treatment of various
ocular diseases. Agents that specifically inhibit the com-
plement system or complement activation products have
been proven beneficial in the treatment of both human and
experimental diseases over the past few years. Thus, the
therapy based on complement inhibition has great potential
in the future for the treatment of various ocular diseases
such as keratitis, uveitis, and macular degeneration.
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